Researchers have discovered a new pathway in the liver that opens the door to treat non-alcoholic fatty liver disease, a condition that affects up to 25 percent of the population and may lead to cirrhosis and eventually liver cancer or failure, and likely other liver diseases and the study was published in Free Radical Biology & Medicine.
The team found that a protein (TRPV4), which is a part of the body's defense system, is able to activate the release of a gas (nitric oxide). This gas then blocks one of the enzymes (CYP2E1) that is a major contributor to non-alcoholic liver disease and its progression. TRPV4 is already known to protect against cardiovascular abnormalities.
Using Trpv4-/- mice and cultured primary cells, authors show that TRPV4 is activated both by damage associated molecular pattern HMGB1 and collagen in diseased Kupffer cells that in turn activate the endothelial NOS (NOS3) to release nitric oxide (NO).
The diffusible NO acts in a paracrine fashion in neighboring hepatocytes to deactivate the redox toxicity induced by CYP2E1. They also find that CYP2E1-mediated TRPV4 repression in late stages causes an unrestricted progression of disease.
Now that this protein's capacity to block the development of non-alcoholic fatty liver disease has been discovered, the next step is to harness its preventive and treatment abilities. According to the authors, a new generation of TRPV4 agonists can now be tested to improve outcomes related to non-alcoholic fatty liver disease. The agonist is a chemical that will bind to this protein and activate the release of nitric oxide to block the harmful enzyme. Once the appropriate agonist is identified, it can be incorporated into medication for clinical treatment.
In addition to revealing the benefits of activating TRPV4, the researchers also warn against the consequences of inhibiting the TRPV4 ion channel, an approach that can enhance hepatotoxicity (i.e., liver damage caused by chemicals), which can result from acetaminophen or alcohol over-consumption.
Non-alcoholic fatty liver disease occurs when there is a buildup of extra fat in the liver (i.e., more that 5-10 percent of the liver's total weight) coupled with liver inflammation that is not caused by alcohol.
http://www.sc.edu/study/colleges_schools/public_health/about/news/2016/new_pathway_treatment_nafld.php
New pathways to treat non-alcoholic fatty-liver disease
- 958 views
- Added
Edited
Latest News
Linking endosomal trafficking to aggressive brain cancer
Overactive food quality control system triggers food allergies
How plants produce defensive toxins without harming themselves
Artificially infect mosquitoes with human malaria to identify new chemicals
Basophil-neuronal axis in acute itch in eczema
Other Top Stories
3D imaging method to identify sperm cells moving at a high speed
How does the brain link events to form a memory?
Circadian network neurons integrate sensory input
ACE2 is higher in mens blood and may help COVID-19 infect cells
Inhibition of sphingolipid metabolism and neurodegenerative diseases
Protocols
Dual-Angle Protocol for Doppler Optical Coherence Tomography to Improve Retinal Blood Flow Measur…
Detection of protein SUMOylation in vivo
In vivo analysis of protein sumoylation induced by a viral protein: Detection of HCMV pp71-induce…
Determination of SUMOylation sites
miR-Selection 3'UTR Target Selection Kit
Publications
An Arf/Rab cascade controls the growth and invasiveness of glioblastoma
Multistage and transmission-blocking targeted antimalarials discovered from the open-source MMV P…
MCT1 Deletion in Oligodendrocyte Lineage Cells Causes Late-Onset Hypomyelination and Axonal Degen…
Familial Alzheimer's Disease Mutations in PSEN1 Lead to Premature Human Stem Cell Neurogenesis
MDA5 Governs the Innate Immune Response to SARS-CoV-2 in Lung Epithelial Cells
Presentations
Homeostasis
PLANT MITOCHONDRIAL BIOLOGY
Photosynthesis
Endocrine Disorders
THE PITUITARY GLAND
Posters
ACMT 2020 Annual Scientific Meeting Abstracts - New York, NY
Abstracts from the 2020 Annual Scientific Meeting of the British and Irish Hypertension Society (…
ACNP 58th Annual Meeting: Poster Session III
ACNP 58th Annual Meeting: Poster Session II
ACNP 58th Annual Meeting: Poster Session I